These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16240471)

  • 1. Erlotinib in lung cancer.
    Pao W; Ladanyi M; Miller VA;
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240471
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib in lung cancer.
    Takano T; Ohe Y
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting EGFR in non-small-cell lung cancer.
    Doroshow JH
    N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimising therapy for EGFR-addicted NSCLC: just the start.
    Govindan R; Subramanian J
    Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing EGFR mutations.
    Marchetti A; Felicioni L; Buttitta F
    N Engl J Med; 2006 Feb; 354(5):526-8; author reply 526-8. PubMed ID: 16452569
    [No Abstract]   [Full Text] [Related]  

  • 6. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib or gefitinib for non-small-cell lung cancer.
    Kaye FJ; Jantz MA; Dallas J
    N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison is beyond IPASS and OPTIMAL.
    Lam KC; Mok TS
    Hong Kong Med J; 2014 Jun; 20(3):176-7. PubMed ID: 24914076
    [No Abstract]   [Full Text] [Related]  

  • 9. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
    Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
    J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
    Lai RS; Xie L; Shen LS; He YM; Zhu CL
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
    [No Abstract]   [Full Text] [Related]  

  • 11. Erlotinib in lung cancer.
    Nabhan C; Bitran JD
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16236747
    [No Abstract]   [Full Text] [Related]  

  • 12. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
    Wong AS; Seto KY; Chin TM; Soo RA
    J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
    [No Abstract]   [Full Text] [Related]  

  • 13. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
    Pennell NA; Yin L; Keshtgarpour M; Ma PC
    J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
    [No Abstract]   [Full Text] [Related]  

  • 14. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
    Langer CJ
    J Clin Oncol; 2007 Mar; 25(7):751-3. PubMed ID: 17228017
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW; Schwander B; Lee VH
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
    Garfield D; Kashef G
    Lung Cancer; 2006 Mar; 51(3):389-90. PubMed ID: 16359750
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
    Gridelli C; Maione P; Galetta D; Rossi A
    J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020
    [No Abstract]   [Full Text] [Related]  

  • 19. Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
    Gadgeel SM
    Clin Lung Cancer; 2006 May; 7(6):369-70. PubMed ID: 16800960
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.